Europe is facing a recent challenge from the United States that could reshape how medicines are priced and accessed across the continent. The policy in question, known as Most Favoured Nation (MFN), ties drug prices in the U.S. To the lowest prices paid in a group of reference countries, many of which are in Europe, including the Czech Republic.
This approach means that pricing decisions made in European capitals no longer remain purely domestic matters. Instead, they directly influence global pharmaceutical economics, potentially affecting the return on investment for research and development by as much as tens of percentage points.
Given that the United States accounts for nearly half of the global pharmaceutical market, the ripple effect of this policy could steer strategic decisions by drug companies regarding where to conduct clinical trials, manufacture medicines, and allocate their research and development portfolios.
the availability of innovative therapies for patients in Europe may be impacted, both in terms of how many new drugs develop into accessible and how quickly they reach the market.
The Czech Republic, far from being a minor player in this system, finds its pricing decisions influencing other countries. Czech drug prices may feed into broader reference mechanisms, increasing the risk that they become part of the lowest benchmarks used under the MFN model.
In response, experts urge strengthening the continent’s pharmaceutical pricing and reimbursement systems to build them more resilient to external pressures. A key element highlighted is preserving the confidentiality of negotiated drug prices between pharmaceutical companies and health insurers.
Equally crucial is ensuring that the true value of innovation is properly reflected in pricing decisions, a step seen as vital to maintaining Europe’s competitiveness and its ability to support life-saving advancements in medicine.
Without timely action, there is a growing concern that Europe’s efforts to sustain innovation and improve access to modern treatments could be undermined by external forces beyond its control.
